AIOS building GLP-1 machine

This reveals that AIOS is building a GLP-1 machine, not a general telehealth brand. Instead of adding new conditions, it reuses the same operating workflow across different customer groups and geographies, from intake forms and clinician review to dose titration, side effect monitoring, pharmacy fulfillment, and monthly refills. That works because GLP-1s are a large, repeat purchase category with enough demand to support multiple front ends on one back end.

• Ro and Hims & Hers started with one simple drug category, then expanded into adjacent conditions because the core workflow stayed similar. AIOS flips that logic. It keeps the molecule constant and changes the customer wrapper, with Fella for men, Delilah for women, and Bolt for UK cash pay patients.
  1 sacra 2 sacra
• The shared ops layer matters more for GLP-1s than for ED or hair loss because care is ongoing. Patients need dose changes, side effect checks, refill management, and reliable cold chain delivery. Ro built owned labs, pharmacies, and home testing to support that heavier workflow, showing why GLP-1 scale comes from operations, not just marketing.
  2 sacra 3 sacra
• The tradeoff is margin versus focus. AIOS reached an estimated $420M annualized revenue in June 2026 and about 150,000 patients by pricing branded GLP-1s at cost in the UK, but that leaves it with pharmacy like gross margins around 20%, well below the 65% to 80% fulfillment margins earned by more vertically integrated telehealth players.
  1 sacra

The next step is geographic replication and eventually drug margin capture. If AIOS can keep buying licensed local pharmacies and plug them into the same operating stack, it can spread one GLP-1 playbook across Europe quickly. Over time, the biggest upside comes if it pairs that distribution engine with generic semaglutide manufacturing once patents begin to roll off.